80 results
Page 2 of 4
8-K
EX-10.3
7d3 u0db3dan
22 May 23
Athira Pharma Appoints Andrew Gengos as Chief Financial Officer and Chief Business Officer
8:00am
8-K
EX-99.1
vnw24m
11 May 23
Athira Pharma Reports First Quarter 2023 Financial Results
4:11pm
8-K
EX-99.1
4uijl
10 Nov 22
Athira Pharma Reports Third Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:11pm
8-K
EX-99.1
5a9 dltjab
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.2
fap0ftt5l wjmhjl9
17 Oct 22
Results support potential clinically meaningful activity of fosgonimeton without background therapy and mitigate program risk
8:30am
8-K
EX-99.1
54a0bwo6 vi
15 Aug 22
Athira Pharma Reports Second Quarter 2022 Financial Results and Recent Clinical and Corporate Updates
4:35pm
8-K
EX-99.1
lnzfhukhu
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
8-K
EX-99.2
ba7b5915q4w6j
22 Jun 22
Athira Pharma Announces Topline Results from ACT-AD Phase 2 Proof of Concept Study of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
7:05am
DEFA14A
8gcyjhuotuwua
17 May 22
Additional proxy soliciting materials
6:06am
DEFA14A
g7qgtszv0m pa5neggs
16 May 22
Additional proxy soliciting materials
6:32pm
8-K
EX-99.1
a4kdtx
12 May 22
Athira Pharma Reports First Quarter 2022 Financial Results
4:12pm
DEFA14A
u6bgk nzv
11 May 22
Additional proxy soliciting materials
4:49pm
DEFA14A
92av3619gmn 1bp1
9 May 22
Additional proxy soliciting materials
4:32pm
DEFA14A
w74skt
5 May 22
Additional proxy soliciting materials
4:00pm
DEFA14A
iyrdzxf
5 May 22
Additional proxy soliciting materials
8:19am
DEFA14A
u9o8ub ycj7ymoln
5 May 22
Additional proxy soliciting materials
8:15am